These findings suggest that the umbilical cord blood CCL17 may be involved in the pathogenesis of infantile AD and in fetomaternal inheritance. Serum levels of CCL17 from umbilical cord blood may be a predictive marker for AD in infancy.

Fixed chirality: The treatment of cyclooctapyrroles (see picture) with a metal source with optically active carboxylate or amine ligands leads to enantioselective metalation to give stereochemically stable helical mononuclear and dinuclear complexes without a chiral auxiliary. The helicity of the dicopper complex was determined by the simulation of the CD spectrum on the basis of X‐ray crystallographic data.

The differences in the inflammatory cytokine value between CSF and serum suggest that the degree of systemic vasculitis is different between CSF and the circulating blood, and some patients with KD showed a higher degree of CSF inflammation.

gem-dimethylisocorrole gave four-coordinate Ni (II) and Cu (II) complexes, five-coordinate (chloro) Fe (III) and (chloro) Mn (III) complexes, and six-coordinate (chloro)(pyridinato) Rh (III) complex in moderate to good yields. The dinuclear complexes such as the μ-oxo-diiron(III) complex and tetracarbonyldirhodium(I) complex were also prepared. The structures of these mononuclear and dinuclear complexes were determined by X-ray crystallography. These structures are very similar to those of the corresponding metaloporphyrins but the presence of the sp3-meso carbon allows tilting of the pyrrole rings so as to adapt itself to various metal coordination geometries.

Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K, Maeda T, Suenobu S-i, Izumi T. The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma. Pediatr Allergy Immunol 2010: 21: 489–492. © 2010 John Wiley & Sons A/STo elucidate the mechanisms of intractable pediatric bronchial asthma and the indication of low-dose erythromycin (EM) therapy, the serum chemokine levels of and the angiogenic factor were evaluated in 55 pediatric patients with bronchial asthma; 7.4 ± 3.5 yr old, who had been treated with inhaled steroid, leukotriene receptor antagonist, theophylline and others for more than a year. Both the levels of interleukin (IL) 8 (p = 0.036) and vascular endothelial growth factor (VEGF) (p = 0.005) were higher in patients with severe type than those of patients with the milder type, while other chemokine levels such as serum eotaxin and MCP1 did not show the correlation with the severity of bronchial asthma. Induction of therapy with low-dose EM induced improvement of the clinical symptoms in patients with severe type and decrease of their serum chemokine levels: IL8; from 736 ± 88 to 75 ± 85 pg/ml (p < 0.0005), and VEGF; from 352.0 ± 160.5 to 132.2 ± 59.9 pg/ml (p = 0.021) within the next 6 months. Moreover, low-dose EM resulted in a decreased daily peak-trough fluctuation rate of the serum theophylline concentration; (Cmax− Cmin)/Cmin, from 1.3 ± 0.5 to 0.5 ± 0.3, which led to the maintenance of effective serum levels. These results indicated that IL8 and VEGF affect the severity of standard therapies resistance intractable bronchial asthma. Through the suppression of these chemokines and maintenance of effective theophylline levels, low-dose EM therapy improves the symptoms of bronchial asthma.